FMR LLC 13D and 13G filings for Poseida Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-07 10:23 am Sale | 2025-01-31 | 13G | Poseida Therapeutics, Inc. PSTX | FMR LLC | 0 0.000% | -10,011,617 (Position Closed) | Filing |
| 2025-02-07 10:06 am Sale | 2024-12-31 | 13G | Poseida Therapeutics, Inc. PSTX | FMR LLC | 10,011,617 10.300% | -4,332,048 (-30.20%) | Filing |
| 2024-02-09 09:28 am Purchase | 2024-02-08 | 13G | Poseida Therapeutics, Inc. PSTX | FMR LLC | 14,343,665 14.999% | 1,451,258 (+11.26%) | Filing |
| 2023-02-09 12:31 pm Purchase | 2023-02-09 | 13G | Poseida Therapeutics, Inc. PSTX | FMR LLC | 12,892,407 14.999% | 3,516,466 (+37.51%) | Filing |
| 2022-02-09 10:24 am Purchase | 2022-02-08 | 13G | Poseida Therapeutics, Inc. PSTX | FMR LLC | 9,375,941 14.999% | 102,940 (+1.11%) | Filing |
| 2021-02-08 10:31 am Purchase | 2021-02-05 | 13G | Poseida Therapeutics, Inc. PSTX | FMR LLC | 9,273,001 14.999% | 619 (+0.01%) | Filing |
| 2020-08-10 09:25 am Purchase | 2020-08-07 | 13G | Poseida Therapeutics, Inc. PSTX | FMR LLC | 9,272,382 14.999% | 9,272,382 (New Position) | Filing |